Depomed (DEPO) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Goldman Sachs raises humanoid robot forecast, sees auto role
- Manhunt underway after woman killed, several injured at Swiss rave shooting
Depomed Reports Second Quarter 2016 Financial Results
August 3, 2016 4:01 PM EDT- Second Quarter Revenues of $117 million, 23% over 2Q 2015 -- NUCYNTA® Franchise Second Quarter 2016 Record Net Sales of $72 million, 27% over 2Q 2015 -- Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below -
NEWARK, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended June 30, 2016.
"The second quarter marked the 1-year anniversary of the mid-June relaunch of our flagship NUCYNTA franchise, said Jim Schoeneck, President and CEO of Depomed. During the first full year after our relaunch, we delivered... More
